PL358408A1 - Zastosowanie Lactobacillus casei w peptydach immunostymulacyjnych - Google Patents

Zastosowanie Lactobacillus casei w peptydach immunostymulacyjnych

Info

Publication number
PL358408A1
PL358408A1 PL01358408A PL35840801A PL358408A1 PL 358408 A1 PL358408 A1 PL 358408A1 PL 01358408 A PL01358408 A PL 01358408A PL 35840801 A PL35840801 A PL 35840801A PL 358408 A1 PL358408 A1 PL 358408A1
Authority
PL
Poland
Prior art keywords
lactobacillus casei
immunostimulatory peptides
immunostimulatory
peptides
casei
Prior art date
Application number
PL01358408A
Other languages
English (en)
Other versions
PL201801B1 (pl
Inventor
Eric Postaire
Benjamin Bonavida
Original Assignee
Compagnie Gervais Danone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL358408(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Compagnie Gervais Danone filed Critical Compagnie Gervais Danone
Publication of PL358408A1 publication Critical patent/PL358408A1/pl
Publication of PL201801B1 publication Critical patent/PL201801B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL358408A 2000-05-25 2001-04-27 Zastosowanie bakteryjnego szczepu CNCM I-1518 do wytwarzania kompozycji przeznaczonej do podawania doustnego PL201801B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0006679A FR2809312B1 (fr) 2000-05-25 2000-05-25 Utilisation de l. casei dans des compositions immunostimulantes

Publications (2)

Publication Number Publication Date
PL358408A1 true PL358408A1 (pl) 2004-08-09
PL201801B1 PL201801B1 (pl) 2009-05-29

Family

ID=8850597

Family Applications (1)

Application Number Title Priority Date Filing Date
PL358408A PL201801B1 (pl) 2000-05-25 2001-04-27 Zastosowanie bakteryjnego szczepu CNCM I-1518 do wytwarzania kompozycji przeznaczonej do podawania doustnego

Country Status (27)

Country Link
US (1) US7604809B2 (pl)
EP (1) EP1283714B1 (pl)
JP (1) JP2003534284A (pl)
CN (1) CN1194707C (pl)
AR (1) AR028626A1 (pl)
AT (1) ATE332143T1 (pl)
AU (2) AU2001256435B2 (pl)
BG (1) BG65884B1 (pl)
BR (1) BR0111135A (pl)
CA (1) CA2410350C (pl)
CZ (1) CZ303600B6 (pl)
DE (1) DE60121327T2 (pl)
DK (1) DK1283714T3 (pl)
EA (1) EA005081B1 (pl)
ES (1) ES2267763T3 (pl)
FR (1) FR2809312B1 (pl)
HR (1) HRP20020935A2 (pl)
HU (1) HUP0302041A3 (pl)
IL (1) IL152980A0 (pl)
MA (1) MA25760A1 (pl)
MX (1) MXPA02011636A (pl)
NO (1) NO332369B1 (pl)
PL (1) PL201801B1 (pl)
PT (1) PT1283714E (pl)
SK (1) SK18272002A3 (pl)
WO (1) WO2001089541A1 (pl)
ZA (1) ZA200209087B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
GB0009294D0 (en) 2000-04-15 2000-05-31 Sec Dep For The Home Departmen Improvements in and relating to analysis of DNA samples
US9610347B2 (en) * 2001-04-30 2017-04-04 Cortcontrol Vaccination response for immunodeficiency or high cortisol
CN1317385C (zh) * 2003-05-30 2007-05-23 上海光明乳业股份有限公司 干酪乳杆菌Bd－II菌株及其在降低血脂方面的应用
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
ATE361101T1 (de) * 2004-08-24 2007-05-15 Nutricia Nv Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
ZA200705844B (en) * 2004-12-15 2008-09-25 Van Der Westhuzen Corne Floris Detoxifying and immunity-booster composition
EP1683425A1 (en) * 2005-01-21 2006-07-26 Compagnie Gervais Danone Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction
ES2264368B1 (es) * 2005-02-11 2007-12-01 Francisco Exposito Mesa Complemento alimenticio o dietetico compuesto por productos procedentes del lisado de microorganismos.
ES2607988T3 (es) 2005-05-31 2017-04-05 Iams Europe B.V. Bifidobacterias probióticas felinas
ATE512211T1 (de) 2005-05-31 2011-06-15 Iams Company Feline probiotische lactobacilli
EP2428225A3 (en) 2006-09-10 2012-05-09 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
FR2912657B1 (fr) * 2007-02-16 2009-04-17 Gervais Danone Sa Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.
WO2009021585A1 (en) * 2007-08-13 2009-02-19 Dsm Ip Assets B.V. Probiotic bacteria for rducing the occurence of symptoms of winter infections
WO2009067000A1 (en) * 2007-11-20 2009-05-28 N.V. Nutricia Composition with synbiotics
EP2119365B1 (de) 2008-05-13 2017-08-16 Glycotope GmbH Fermentationsprozess
AU2009248410B2 (en) * 2008-05-13 2014-07-24 Glycotope Gmbh Fermentation process
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
EP2153837A1 (en) * 2008-08-14 2010-02-17 Compagnie Gervais Danone Compositions comprising Lactobacillus casei for improving resistance to common infectious diseases
FR2937252B1 (fr) * 2008-10-17 2011-05-20 Pf Medicament Association d'un extrait de sureau et d'une souche de l. paracasei.
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
ES2587136T3 (es) * 2010-01-08 2016-10-20 Compagnie Gervais Danone Lactobacilos con acción antioxidante
EP2545160B1 (en) * 2010-03-12 2018-07-18 Compagnie Gervais Danone Lactic acid bacteria for coeliac disease
CN103220921B (zh) * 2010-10-15 2015-12-16 科.汉森有限公司 免疫佐剂
EP2455092A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
BR112014004065A2 (pt) 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor
WO2014038929A1 (en) 2012-09-07 2014-03-13 N.V. Nutricia Probiotics for producing antiviral factors
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05236872A (ja) * 1992-02-27 1993-09-17 Takanashi Nyugyo Kk 乳酸菌含有食品
JP4112021B2 (ja) * 1994-02-16 2008-07-02 明治乳業株式会社 乳酸菌を用いた免疫賦活剤
DE69506002T2 (de) * 1995-01-02 1999-06-24 Compagnie Gervais Danone, Levallois-Perret Milchsäureferment, und ihre verwendung zur herstellung von antidiarrhöeprodrukten
GB2338245B (en) * 1997-08-21 2001-11-21 New Zealand Dairy Board Immunity enhancing lactic acid bacteria
US6699517B2 (en) * 1997-11-28 2004-03-02 Compagnie Gervais Danone Method for preparing food products by fermenting soy milk with streptococcus thermophilus
IT1298918B1 (it) * 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
KR100324441B1 (ko) * 1999-02-08 2002-02-27 이은선 위염, 위궤양, 십이지장궤양 예방을 위한 식품

Also Published As

Publication number Publication date
US7604809B2 (en) 2009-10-20
CN1194707C (zh) 2005-03-30
DE60121327T2 (de) 2007-07-26
CA2410350A1 (fr) 2001-11-29
HRP20020935A2 (en) 2005-02-28
CZ20024189A3 (cs) 2003-05-14
ZA200209087B (en) 2004-06-30
EA005081B1 (ru) 2004-10-28
ATE332143T1 (de) 2006-07-15
EA200201248A1 (ru) 2003-06-26
NO20025595D0 (no) 2002-11-21
HUP0302041A3 (en) 2005-11-28
AU2001256435B2 (en) 2006-06-29
JP2003534284A (ja) 2003-11-18
EP1283714B1 (fr) 2006-07-05
SK18272002A3 (sk) 2003-08-05
FR2809312A1 (fr) 2001-11-30
AU5643501A (en) 2001-12-03
DE60121327D1 (de) 2006-08-17
CZ303600B6 (cs) 2013-01-02
PT1283714E (pt) 2006-11-30
NO332369B1 (no) 2012-09-03
BG107299A (bg) 2003-07-31
CA2410350C (fr) 2013-04-09
MA25760A1 (fr) 2003-04-01
AR028626A1 (es) 2003-05-14
ES2267763T3 (es) 2007-03-16
WO2001089541A1 (fr) 2001-11-29
CN1430518A (zh) 2003-07-16
FR2809312B1 (fr) 2002-07-12
IL152980A0 (en) 2003-06-24
NO20025595L (no) 2003-01-22
BR0111135A (pt) 2003-04-08
DK1283714T3 (da) 2006-10-30
PL201801B1 (pl) 2009-05-29
HK1055898A1 (en) 2004-01-30
HUP0302041A2 (hu) 2003-09-29
EP1283714A1 (fr) 2003-02-19
MXPA02011636A (es) 2003-05-14
BG65884B1 (bg) 2010-04-30
US20040029127A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
HUP0302041A3 (en) Use of lactobacillus casei in immunostimulatory peptides
AU2001256435A1 (en) Use of lactobacillus casei in immunostimulatory compositions
HUP0301003A3 (en) Casein derived peptides and uses thereof in therapy
IL153970A0 (en) Promyostatin peptides and methods of using same
IL160050A0 (en) Probiotic lactobacillus casei strains
AU7616001A (en) Probiotic recolonisation therapy
AU2002365396A8 (en) Peptides, peptide compositions,and methods of use in binding p 185
AU6723401A (en) Antimicrobial peptides and methods of use thereof
HUP0600031A3 (en) Kahalalide formulations and their use
IL153671A0 (en) Amphipathic linear peptides and formulations containing same peptides
IL160548A0 (en) Casein derived peptides and uses thereof in therapy
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
GB0026134D0 (en) Peptides and their use
PL362753A1 (pl) Nowy szczep Lactobacillus paracasei
SG97174A1 (en) Lactobacillus rhamnosus strain and uses thereof
IL145527A0 (en) Retro-inverso prosaposin-derived peptides and use thereof
GB0017028D0 (en) Peptides and their therapeutic use
IL151351A0 (en) Casein derived peptides and uses thereof in therapy
GB0026135D0 (en) Peptides and their use
GB0018148D0 (en) Peptides and their use
EP1300416A4 (en) PEPTIDE FOR INCREASING THE MEMORY AND ITS APPLICATIONS
HK1051501A (en) Casein derived peptides and uses thereof in therapy
AU5995701A (en) Synthetic peptides and uses therefore
GB0002560D0 (en) Virulence gene and protein and their use
GB0003725D0 (en) Virulence gene and protein and their use